Methods: Articles on the effects of obesity on LARS were identified from Ovid Medline, EMBASE and the Cochrane Library databases up to 30th of November 2016. Two independent searches were conducted. Data were extracted independently by two researchers. The primary outcome was recurrence, whilst the secondary outcome was operative time.
Introduction
Obesity is increasing worldwide at an alarming rate. In the US, obesity doubled between 1980 and 2002, while the number of overweight tripled during the same period. 1 According to the 2008 World Health Organisation (WHO) report 50% of both men and women in the Europe were overweight, and roughly 20% of men and 23% women were obese. These data were considerably higher than in a WHO report published in 2005, with 23 .2% of whole world population being overweight and 9.8% obese. 2 Gastroesophageal reflux disease (GORD) is a reasonably common disease. About 20% of the adult population in western countries suffer from GORD. 3, 4 The symptoms of GORD include heartburn, globus sensation, epigastric pain, chest pain, dyspepsia, and dysphagia. 3 The complications of GORD vary from reflux oesophagitis, erosive oesophagitis, Schatzki ring formation, Barrett's oesophagus 5 and adenocarcinoma. 6, 7 Medical management is the cornerstone of the initial management, following life style modifications. PPI therapy has shown remarkable long-term safety 8 and is the most commonly prescribed medication.
Although it is still controversial as to whether obesity predisposes people to gastroesophageal reflux disease, 9e11 with such a high prevalence of obesity, surgeons are required to treat patients categorised as obese with anti-reflux surgery. Since the availability of laparoscopic anti-reflux surgery (LARS), the threshold for offering surgery to patients with GORD has changed. LARS is extremely effective in controlling GORD symptoms. Indications for LARS include persistent or recurrent acid reflux after acid suppression therapy, increased oesophageal acid exposure, and mechanically defective lower oesophageal sphincter on manometry. 12 Relative indications include non-compliant patients, patients on very high doses of medication and patients too young for lifetime medical treatment. 13 Multiple studies showed that surgical approach is superior to medical management alone for refractory cases of the gastroesophageal reflux disease. 14, 15 Laparoscopic anti-reflux surgery (LARS) includes laparoscopic Nissen fundoplication (LNF), which is considered as gold standard surgery for GORD. It involves using a wrap of fundus of stomach, which is passed through a space created behind oesophagus, dividing short gastric arteries near the fundus to make it mobile enough to be used as a wrap, and stitching this to the other side making a 360 circle around the lower oesophagus. The long-term effectiveness of LNF is reported in several studies. 16e18 Laparoscopic toupet (LT) is a 270 posterior wrap, which is commonly carried out in patients with symptoms of dysphagia to avoid exaggeration of postoperative dysphagia. Studies have shown it to be as effective as LNF. 19, 20 Other modifications involve 180 anterior and posterior wraps, and are all categorised as LARS. It is unclear if LARS is as effective in obese patients as it is in non-obese patients. 21, 22 Moreover, it is not known if the surgery is more complex or difficult for obese patients. With ever increasing obesity rates and controversial results about the effect of obesity on the recurrence rates, we felt a need to clarify the impact of obesity on the success of anti-reflux surgery.
Methods

Protocol and registration
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 23 was used for reporting. The study was registered with International Prospective Registry for Systematic reviews (PROSPRO), registration number CRD42016050601.
Eligibility criteria
The PICO model was used to devise the search criteria, defined in detail in Table 1 . We included studies which included data on both obese and non-obese patients. Specifically, we included patients who were obese (body mass index (BMI) 30 kg/m 2 ), 24 with acid reflux disease, and who underwent LARS for relief of GORD (first-time surgery only). As a comparison group, we recorded the details of non-obese patients (BMI <30 kg/m 2 ) with acid reflux disease, who underwent LARS for relief of GORD. The outcomes of interest were recurrence (the primary outcome) and operative time (the secondary outcome). Both prospective and retrospective studies were included. Articles missing primary outcome, expert opinions, reviews, studies on patients undergoing LARS for the second or subsequent time, data on patients under 18 years, and conference proceedings that later resulted in full research were excluded. 
Study selection
After duplicates removed, all the studies identified in the search were screened independently by two reviewers (YB and RM), using article titles and abstracts against predefined inclusion and exclusion criteria. If there was any conflict about a study, it was resolved with consensus. Conference proceedings were included if they met the inclusion criteria and had the required information. The reviewers were not blinded regarding the authors or the institutions of the studies. In the case of missing data, corresponding authors were contacted by email.
Data extraction and items
Data were extracted by two independent researchers (YB and QU) using predetermined data extraction form. The initial part included general information about the article and assessed whether it contained the primary and secondary outcomes of interest. Studies containing at least the primary outcome (recurrence) were included. 'Recurrence' was defined as "recurrence of the reflux symptoms". Operative time (secondary outcome) was measured in minutes.
Quality assessment and risk of bias
The quality of each individual study was assessed independently by two reviewers (YB and RM), using the NewcastleeOttawa Scale, 25 which employs a star scoring system for the quality assessment of studies. A total of 9 stars can be awarded to a study. A study can be awarded a maximum of 4 for selection, 3 for outcome and maximum of 2 stars for comparability. Studies were categorised as low, moderate and high quality depending on the number of stars; 0e3 were low quality, 4e6 were medium quality and 7e9 were high quality.
Summary measures and synthesis of results
We calculated risk ratio and confidence interval (CI) for the primary outcome, while difference in means and CI was calculated for the secondary outcome using meta-analysis software Review Manager (RevMan) Version 5.3 26, 27 (Copenhagen: The Nordic COCHRANE Collaboration, 2014). A random effects model was used which gives us a more conservative estimate of the effect of obesity on LARS. Studies which reported recurrence after objective assessment by investigations were analysed separately to have more critical view of effect of obesity on recurrence after LARS. Forest Plots and Funnel Plots were also created using this software. Data for recurrence were also analysed for Pearson Chi-Square using SPSS version 23 (IBM corporation USA licenced 1989, 2015).
Using the above-mentioned software, a pooled estimate of recurrence and operative time from all the included studies was calculated. Statistical heterogeneity among the studies was calculated using I 2 (values ranged between 0% and 100%, with values closer to 0% indicating less heterogeneity). I 2 describes the percentage of variation among studies caused by heterogeneity rather than by chance. A P-value of less than 0.05 was considered significant, where appropriate.
Results
Study selection
The number of articles found through electronic search of Ovid Medline, EMBASE and COCHRANE library were 5191. Further 44 articles were found through other means, which included hand searching through the bibliography of relevant articles. The total after adding both was 5235. After duplicates were removed, the number of articles was 4282. Screening of these articles was done using title and abstract of the articles, removing another 4257, leaving 25 articles to be assessed with full text. The full text of 25 articles was studied in detail and 12 studies were included in our qualitative and quantitative analysis. Five studies 28e32 who reported recurrence depending on objective assessment were analysed separately as well to have more accurate measurement of effect of obesity on recurrence after LARS. The studies which were excluded after reviewing full text included six 21,33e36 which were missing the primary outcome or where the primary outcome could not be calculated from the available data. Two studies 37, 38 grouped the patients according to BMI, but the categorisation differed from ours, and therefore the data were not amenable to metaanalysis. One study 39 categorised patients according to weight only, and data provided were not enough to calculate BMI. One article 40 was expert opinion and contained no original data.
Another divided patient according to results, and therefore data could not be extracted. One conference presentation 41 later became a full publication 30 which was included. One paper 42 had only obese patients, so was excluded. See Fig. 1 for search summary.
Study characteristics
The characteristics of the studies included are detailed in Table 2 . Four studies were from the USA, 29 
Assessment of studies
Study quality was assessed using NewcastleeOttawa Scale. All studies scored seven stars or more (of a possible 9 stars) on Full-text ar cles assessed for eligibility (n = 25)
Full-text ar cles excluded, with reasons (n = 13)
Studies included in qualita ve synthesis (n =12)
Included
Studies included in quan ta ve synthesis (meta-analysis) (n =12)
Studies with Objec ve assessment(meta-analysis) (n=5) Fig. 1 e PRISMA flowchart, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. This summarize the selection of studies in meta-analysis. No effect 7* t h e s u r g e o n x x x ( 2 0 1 8 ) 1 e1 2 this scale, so were deemed to be high quality studies. They ranged between seven stars 31, 43e48 and nine stars. 32 There was 100% agreement on quality of the studies between the two reviewers (YB and RM). 
Results of studies
Synthesis of results
The total pooled number of patients in all the studies was 3346, specifically 923 obese patients and 2423 non-obese patients. Based on a random effect model, the overall risk ratio for recurrence after LARS in obese versus non-obese patients was 1.36 (95% CI 1.08e1.72) (Fig. 2) , with non-obese patients having less recurrence (see Fig. 2 ). When studies which reported recurrence based on objective assessment were analysed separately, there were 1517 patients in non-obese group and 458 in obese group. Risk ratio was 1.53(95% CI 1.01e2.32) based on fixed effect model showing more clearly that there is a definitely an increased risk of recurrence of GORD after LARS in obese patients as compared to non-obese patients (Fig. 3 ).
There was minimal heterogeneity among the studies for recurrence (I 2 ¼ 0%). When included in the funnel plot (Fig. 4) most of the studies were very close to the overall result of the meta-analysis. Smaller studies are towards the bottom of the funnel plot while larger studies are towards the top of the inverted funnel. Using a random effect model, the mean difference in operative time between obese and non-obese patients was 13.94 min (95% CI 9.33e18.55). Two studies did not have secondary outcomes. 46, 48 There was significant heterogeneity among the studies with I 2 ¼ 96%. Figure 5 shows that obese patients had significantly longer operative times that non-obese patients. A funnel plot of the operative time shows larger studies towards the top of inverted funnel (Fig. 6 ).
Additional analysis
Additional analysis of recurrence in obese versus non-obese patients who underwent LARS, was done. A chi-square test showed that there was statistically significant relationship between obesity and recurrence (p < 0.005).
Discussion
To our knowledge, this is the first meta-analysis to be conducted on the effect of obesity on laparoscopic anti-reflux surgery (LARS) registered with PROSPERO and online since 1/ 11/2016 with registration number CRD42016050601. There are enormous difference of opinion on the effect of obesity on recurrence after LARS, varying from adverse effects 28, 30, 46, 48 surgery for obese patients is more challenging, as can be seen by the longer operative time for the obese patients. Perez et al. 30 were the first to suggest that obesity adversely effects LARS. They were of the opinion that thoracic approach would bring better results, however their results showed that obesity negatively effects both the procedures. Later, multiple studies were done to examine the effect of obesity on LARS with conflicting results. We divided the patients into obese and non-obese patients, using WHO criteria. 49 Operating on obese patients is technically more difficult, chances of having perioperative complication are higher and the more risk is associated with surgical procedures in obese patients. 50e53 Although LARS has proven benefits for patients with GORD, it is important to establish if there is long term relief of symptoms. This meta-analysis determines that obesity increases the chance of recurrence of symptoms of GORD after LARS. Additionally, our results show that obesity is associated with longer operative time in laparoscopic anti-reflux surgery. It is previously shown by multiple studies that longer operative time is associated with increased infection rates and other complications in laparoscopic surgery. 54, 55 Multiple factors are thought to be responsible in the pathophysiology of GORD in obese. Hiatal hernias are more 
pre-valent among the obese which could be cause of GORD.
Obese patients have increased intra-abdominal pressure that displaces the lower oesophageal sphincter and increases the gastro-oesophageal gradient. And vagal abnormalities associated with obesity may cause a higher output of bile and pancreatic enzymes which aggravates problem for obese patients. 56 And the risk of major complications for obese patients is higher than normal BMI patients following surgery. 57 The findings of this meta-analysis are significant and in the sense that individual studies (mostly) do not show that there is increased risk of recurrence for obese patients but the collective pooled result of the meta-analysis clearly showed that there is statistically significant increase in recurrence for obese patients compared to non-obese patients.
Studies demonstrate that there is marked improvement in GORD in obese patients after weight loss. 58, 59 Suggesting that weight reduction should be suggested to patients for improvement in symptoms and it will also reduce the chances of recurrence of symptoms in patients as shown by our metaanalysis. Another alternative could be some bariatric procedures having additional benefit of diminishing symptoms of GORD. 60, 61 One might argue that meta-analysis should be conducted for randomised controlled trials, however due to lack of randomised studies in many areas the meta-analysis is being conducted for non-randomised studies as well and studies have shown that they generally produce estimates of effect similar to those from meta-analyses bases on randomized controlled trials. This is identified by many researchers and led to formation of MOOSE guidelines, recognising that observational studies can be used for meta-analysis. 62 
Summary of evidence
Individual studies on this topic failed to point to a clear conclusion regarding the effects of obesity on LARS, and no meta-analysis had previously been done. In this metaanalysis, data from 12 studies conducted between 2001 and 2013 was pooled and analysed.
The methodological quality of the studies included in this meta-analysis was good to excellent. The surgical techniques were standardised in all the studies and were explained in detail. Recurrence in obese (BMI > 30) vs non-obese (BMI < 30) patients using random effect model, showed a relative risk of 1.36 (95%CI 1.08e1.72, p < 0.05) for obese patients. Three articles included in the meta-analysis are conference papers so we leave to readers to decide and interpret results keeping that in mind.
We further analysed the studies to rectify this weakness and included studies which objectively assessed the recurrence and full published articles (See Table 3 ) and the results showed relative risk of 1.53 (95% CI 1.01e2.32, p ¼ 0.05). This shows that there is 53% more risk of recurrence for obese patients as compared to non-obese patients. The whole of the diamond of forest plot for recurrence favours non-obese with sides (95% confidence interval) on the same side. If we look at the forest plot for recurrence, at first glance, it is obvious that all the studies overlap and there are no outlier results, showing homogenous results in studies. So, whether the recurrence is defined as symptom recurrence or actual acid reflux proven by investigations, in both cases statistically significant, more recurrence was present in obese as compared to non-obese patients.
In the meta-analysis, we also analysed the operative time for the LARS for obese vs non-obese patients. Results showed that obese patients require technically more difficult surgery compared to non-obese patients. This can be easily seen from the mean difference in operative time of 13.94 min between the two groups. With a significantly longer operative time for the obese group. A similar outcome was seen in laparoscopic colorectal surgery in obese and non-obese patients were seen in a meta-analysis by Zhou et al. 63 They concluded that obesity is associated with increased conversion rates, operating time and post-operative morbidity in laparoscopic colorectal surgery. This can be explained with the fact that more visceral fat and poorly defined tissue planes lead to more difficult surgery. Similar results were found in our study. 
Although the definition of operative time was not defined by the studies, that led to severe heterogeneity of 96% in the results, all the studies showed longer operative times for the obese vs non-obese patients indicating that surgery in obese patients is technically more challenging.
In conclusion, surgeons should be cautious about offering laparoscopic anti-reflux surgery to obese patients. They should always assess that the severity of the disease is worth taking the risks of the surgery for obese patients and benefits should always overweigh the risks. And if it is offered to obese patients, they should be explained and patient should understand the additional risk of recurrence and longer operative times compared to non-obese patients.
Extensive and exhaustive literature search was done as search strategy was developed with help of librarians. The sensitivity of the search strategy was very high and specificity low which was intentional in order to capture all the available studies. The pooling of the data using predefined data extraction forms and then statistical analysis, showed very low heterogeneity for recurrence indicating that the results are homogenous among the studies. We also used the chisquare test to show that the difference in recurrence between the two groups is statistically significant. It shows a statistically significant relationship between obesity and recurrence after LARS.
Limitations
In this meta-analysis, operative time of surgery was analysed. It was found that there was huge heterogeneity between the studies. This was because operative time was never explained in detail. It might be the total time spent in the theatre from intubation to extubation, or the actual time of surgery. But as explained before, regardless of this, all the studies showed statistically longer operative times for obese patients.
Conclusion
In conclusion, the meta-analysis demonstrates that there are significantly increased recurrence rates in obese patients who undergo LARS as compared to non-obese patients, therefore we recommend that patients be informed of this higher likelihood for recurrence as part of the medical and surgical workup. In addition to higher recurrence rates, operative times for obese patients are higher than for non-obese patients, proving that as a procedure, LARS is more demanding in this patient population.
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